Pharmacodynamic effects of adjunctive high dose atorvastatin on double dose clopidogrel in patients with high on-treatment platelet reactivity depending on diabetes mellitus status

Journal of Thrombosis and Thrombolysis

Volumn 37, Issue 4, 2014, Pages 427-434

  Leoncini, Mario ^a   Toso, Anna ^a   Maioli, Mauro ^a   Angiolillo, Dominick J ^b   Giusti, Betti ^c   Marcucci, Rossella ^c   Abbate, Rosanna ^c   Bellandi, Francesco ^a  

^a MISERICORDIA E DOLCE HOSPITAL   (Italy)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Clopidogrel; Diabetes; High dose statins; VerifyNow assay

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; ATORVASTATIN; CLOPIDOGREL; CREATININE; INSULIN; ANTITHROMBOCYTIC AGENT; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRROLE DERIVATIVE; TICLOPIDINE;

ADJUVANT THERAPY; AGED; ARTICLE; BARE METAL STENT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATININE CLEARANCE; DIABETES MELLITUS; DRUG ELUTING STENT; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESPONSE; EVENING DOSAGE; FEMALE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORNING DOSAGE; PERCUTANEOUS CORONARY INTERVENTION; PHARMACODYNAMICS; PLATELET REACTIVITY; POST HOC ANALYSIS; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION INHIBITION; ANALOGS AND DERIVATIVES; BLOOD; COMPARATIVE STUDY; DRUG EFFECTS; MIDDLE AGED; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE ACTIVATION; THROMBOSIS;

AGED; DIABETES MELLITUS; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; PYRROLES; THROMBOSIS; TICLOPIDINE;

EID: 84899945598     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-013-0966-0     Document Type: Article

References (36)

1. Marcucci R, Gori AM, Paniccia R et al (2009) Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 119:237-242
2. Brar SS, ten Berg J, Marcucci M et al (2011) Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention: a collaborative meta-analysis of individual participant data. J Am Coll Cardiol 58:1945-1954
3. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al (2007) Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 49:1505-1516 (Pubitemid 46517957)
4. Bhatt DL (2012) Antiplatelet therapy following myocardial infarction in patients with diabetes. JAMA 308:921-922
5. Ferroni P, Basili S, Falco A et al (2004) Platelet activation in type 2 diabetes mellitus. J Thromb Haemost 2:1282-1291 (Pubitemid 40186123)
6. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al (2005) Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 54:2430-2435 (Pubitemid 41134272)
7. Angiolillo DJ, Bernardo E, Ramirez C et al (2006) Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. J Am Coll Cardiol 48:298-304 (Pubitemid 44026661)
8. Ferreira IA, Mocking AI, Feijge MA et al (2006) Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 26:417-422 (Pubitemid 43732209)
9. Jl Ferreiro, Angiolillo DJ (2011) Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation 123:798-813
10. Hess K, Marx N, Lehrke M (2012) Cardiovascular disease and diabetes: the vulnerable patients. Eur Heart J 14(suppl B):B4-B13
11. Andersson C, Lyngbæk S, Nguyen CD et al (2012) Association of clopidogrel treatment with risk of mortality and cardiovascular events following myocardial infarction in patients with and without diabetes. JAMA 308:882-889
12. Angiolillo DJ, Shoemaker SB, Desai B et al (2007) Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 115:708-716 (Pubitemid 46294761)
13. Angiolillo DJ, Capranzano P, Goto S et al (2008) A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. Eur Heart J 29:2202-2211
14. Angiolillo DJ, Badimon JJ, Saucedo JF et al (2011) A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. Eur Heart J 32:838-846
15. Angiolillo DJ, Capranzano P, Ferreiro JL et al (2011) Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy. Thromb Haemost 106:253-262
16. Capranzano P, Ferreiro JL, Ueno M et al (2013) Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: impact of high on-treatment platelet reactivity and diabetes mellitus status. Catheter Cardiovasc Interv 81:42-49
17. Wiviott SD, Braunwald E, Angiolillo DJ, TRITON-TIMI 38 Investigators et al (2008) Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 118:1626-1636
18. James S, Angiolillo DJ, Cornel JH et al PLATO Study Group (2010) Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 31:3006-3016
19. Ueno M, Ferreiro JL, Tomasello SD et al (2011) Impact of pentoxifylline on platelet function profiles in patients with type 2 diabetes mellitus and coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. JACC Cardiovasc Interv 4:905-912
20. Suryadevara S, Ueno M, Tello-Montoliu A et al (2012) Effects of pioglitazone on platelet P2Y12-mediated signalling in clopidogrel-treated patients with type 2 diabetes mellitus. Thromb Haemost 108:930-936
21. Vivas D, García-Rubira JC, Bernardo E et al (2011) Effects of intensive glucose control on platelet reactivity in patients with acute coronary syndromes. Results of the CHIPS Study ("Control de Hiperglucemia y Actividad Plaquetaria en Pacientes con Sindrome Coronario Agudo"). Heart 97:803-809
22. Davidson MH (2005) Clinical significance of statin pleiotropic effects hypotheses versus evidence. Circulation 111:2280-2281
23. PignatelliP Carnevale R, Pastori D et al (2012) Immediate antioxidant and antiplatelet effect of atorvastatin via inhibition of Nox2. Circulation 126:92-103
24. Piorkowski M, Fischer S, Stellbaum C et al (2007) Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets? J Am Coll Cardiol 49:1035-1042 (Pubitemid 46349499)
25. Leoncini M, Toso A, Maioli M et al (2013) Impact of high dose atorvastatin on the pharmacodynamic effects of double dose clopidogrel in patients undergoing percutaneous coronary interventions: the ACHIDO (Atorvastatin and Clopidogrel HIgh DOse in stable patients with residual high platelet activity) study. JACC Cardiovasc Interv 6(2):169-179
26. Bonello L, Tantry US, Marcucci R et al (2010) Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 56:919-933
27. Saracini C, Vestrini A, Galora S et al (2012) Pharmacogenetics of clopidogrel: comparison between a standard and a rapid genetic testing. Genet Test Mol Biomarkers 16:500-503
28. Han Y, Li Y, Wang S et al (2009) Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. Am Heart J 157:733-739
29. Barker CM, Murray SS, Teirstein PS et al (2010) Pilot Study of the antiplatelet effect of increased clopidogrel maintenance dosing and its relationship to CYP2C19 genotype in patients with high on-treatment reactivity. J Am Coll Cardiol Intv 3:1001-1007
30. Patti G, Greco D, Dicuonzo G et al (2011) High versus standard clopidogrel maintenance dose after percutaneous coronary intervention and effects on platelet inhibition, endothelial and inflammation: results of the ARMYDA-150 mg (antiplatelet therapy for reduction of myocardial damage during angioplasty) randomized study. J Am Coll Cardiol 57:771-778
31. Ari H, Ozkan H, Karacinar A et al (2012) The EFFect of hIgh-dose ClopIdogrel treatmENT in patients with clopidogrel resistance (The EFFICIENT Trial). Int J Cardiol 157:374-380
32. Price MJ, Berger PB, Teirstein PS, Investigators GRAVITAS et al (2011) Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305:1097-1105
33. Collet JP, Cuisset T, Rangé G, Investigators ARCTIC et al (2012) Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 367:2100-2109
34. Cholesterol Treatment Trialists' (CTT) Collaborators (2008) Efficacy of cholesterol-lowering therapy in 18686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371:117-125
35. Feidt DM, Klein Kathrin et al (2010) Profiling induction of cytochrome P450 enzyme activity by statins using a new liquid chromatography-tandem mass spectrometry cocktail assay in human hepatocytes. Drug Metab Dispos 38:1589-1597
36. Gajos G, Rostoff P, Undas A et al (2010) Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI (OMEGA-3 fatty acids after pci to modify responsiveness to dual antiplatelet therapy) study. J Am Coll Cardiol 55:1671-1678